Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
Molecular Oncology · 2023-08 · 17 (8) · 1581-1594
DOI: 10.1002/1878-0261.13439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 29.04.2023. Verfasst von Hai-Yan Tu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzh…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The efficacy of immunotherapy in advanced HER2 ‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)‐based therapy efficacy between patients with ex20ins and non‐ex20ins. Two external cohorts (TCGA, n = 21; META‐ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death‐ligand 1 (PD‐L1) expression < 1%. Compared with ex20ins patients, non‐ex20ins patients had more concurrent mutations in the GLCI cohort ( P < 0.01) and a higher tumour mutation burden in the TCGA cohort ( P = 0.03). Under ICI‐based therapy, advanced NSCLC patients with non‐ex20ins had potentially superior progression‐free survival [median: 13.0 vs . 3.6 months, adjusted hazard ratio (HR): 0.31, 95% confidence interval (CI): 0.11–0.83] and overall survival (median: 27.5 vs. 8.1 months, adjusted HR: 0.39, 95% CI: 0.13–1.18) to ex20ins patients, consistent with findings in the META‐ICI cohort. ICI‐based therapy may serve as an option for advanced HER2 ‐mutated NSCLC, with potentially better efficacy in non‐ex20ins patients. Further investigations are warranted in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., China.
- Guangdong Lung Cancer Institute, Medical Research Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Hematology, First Affiliated Hospital, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China.
ORCID-Profile: Hai-Yan Tu, Xiaotian Zhao, Chong-Rui Xu, Jin-Ji Yang, Qiuxiang Ou, Yi-Long Wu
Zitieren
APA
Tu, H. Y., Yin, K., Zhao, X., Ke, E. E., Wu, S. P., Li, Y. S., Zheng, M. M., Liu, S. M., Xu, C. R., Sun, Y. L., Lin, J. X., Bai, X. Y., Zhang, Y. C., Zhou, Q., Yang, J. J., Zhong, W. Z., Wang, B. C., Zhang, X. C., Zhu, D., …, & Wu, Y. L. (2023). Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy. Molecular Oncology, 17(8), 1581-1594. https://doi.org/10.1002/1878-0261.13439
Vancouver
Tu HY, Yin K, Zhao X, Ke EE, Wu SP, Li YS, et al. Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy. Molecular Oncology. 2023;17(8):1581-1594. doi:10.1002/1878-0261.13439
BibTeX
@article{Tu2023,
author = {Tu, Hai-Yan and Yin, Kai and Zhao, Xiaotian and Ke, E-E and Wu, Si-Pei and Li, Yang-Si and Zheng, Mei-Mei and Liu, Si-Yang Maggie and Xu, Chong-Rui and Sun, Yue-Li and Lin, Jia-Xin and Bai, Xiao-Yan and Zhang, Yi-Chen and Zhou, Qing and Yang, Jin-Ji and Zhong, Wen-Zhao and Wang, Bing-Chao and Zhang, Xu-Chao and Zhu, Dongqin and Yang, Lingling and Ou, Qiuxiang and Wu, Yi-Long},
title = {Genomic and immune characteristics of HER2 ‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy},
journal = {Molecular Oncology},
year = {2023},
volume = {17},
number = {8},
pages = {1581--1594},
doi = {10.1002/1878-0261.13439}
}
EUVIMED